Labcorp launches labcorp® plasma detect™ extending leadership into molecular residual disease (mrd) clinical research

Labcorp plasma detect is the first clinically validated, whole-genome sequencing mrd solution for early-stage colon cancer burlington, n.c. , april 5, 2024 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, announced today the launch of labcorp® plasma detect™, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor dna (ctdna) molecular residual disease (mrd) solution in early stage colon cancer to identify patients at increased risk of recurrence after surgery or adjuvant chemotherapy (act).
LH Ratings Summary
LH Quant Ranking